BPC-157 TB-500 Combination Recovery
TL;DR
The BPC-157 + TB-500 combination for musculoskeletal recovery has zero human evidence in any species. No clinical trial — completed, ongoing, or planned — has tested the combination. Neither peptide has human efficacy data for musculoskeletal indications. Common lore about dosing, half-life, and oral bioavailability is not supported by primary literature. Athletes subject to anti-doping testing face real, documented risk from TB-500 despite its monitoring-only WADA status. NSAID co-use creates a clinically actionable counseling gap: BPC-157 is gastroprotective in rodents, but whether it blunts NSAID anti-inflammatory efficacy at injury sites is unknown.
Vitals Relevance
- Attribution impossible: Zero human efficacy data means no wearable signal can be attributed to either peptide
- Anti-doping: TB-500 positive cases exist (PMID 37515313); competitive athletes in Vitals user base face real WADA risk
- NSAID co-use: Directionality unknown — a genuine counseling gap for injury recovery populations
- Grey-market quality: Structural quality risk (no regulatory QA) must precede any protocol discussion
- Key pending data: NCT07437547 (BPC-HAMSTR, BPC-157 Phase II hamstring strain, N=120) will not report until 2027+; NCT07487363 (TBRIDGE-CV, first-in-human TB-500 fragment trial) also not until 2027
Key Facts
Compound Identity
| BPC-157 | TB-500 | |
|---|---|---|
| Full name | Stable Gastric Pentadecapeptide BPC 157 | Thymosin Beta-4 17–23 fragment |
| Sequence | 15 aa (~1.5 kDa) | 7 aa fragment of 43-aa Tβ4 (~4.9 kDa full-length) |
| Regulatory status | Not FDA/EMA approved; research chemical | Not FDA/EMA approved; WADA Monitoring Program |
| Human data | IBD trials only (not musculoskeletal) | Zero published human trials for fragment |
Evidence Ceiling
| Claim | Grade | Source |
|---|---|---|
| Zero human MSK efficacy data for BPC-157 | P0 confirmed | Clinical worker + monograph |
| Zero human efficacy data for TB-500 in any indication | P0 confirmed | Clinical worker |
| Zero combination study in any species | P0 confirmed | All workers |
| Zero formal human PK for either peptide | P0 confirmed | PK worker (PMID 36588717, PMID 9226473) |
Critical Corrections to Common Lore
| Claim | Truth |
|---|---|
| ”85% oral BPC-157 bioavailability” | Fabricated. No peer-reviewed primary citation exists. No oral bioavailability measured in any species. |
| ”BPC-157 plasma half-life 4–6 hours” | Incorrect. Formal PK (PMID 36588717): plasma t½ <30 min in rats and dogs. Tissue radioactivity persistence ≠ intact peptide half-life. |
| ”TB-500 is safe / not prohibited” | Partially false. WADA Monitoring Program (not prohibited) — but positive doping cases documented (PMID 37515313). LOD 0.19 ng/mL via Ac-Tβ1-14 metabolite assay. |
| ”TB-500 works orally” | Pseudoscientific. At ~4.9 kDa, TB-500 exceeds the empirical oral absorption threshold (~1 kDa) by ~5×. No enabling technology applied. |
Mechanism Summary
The combination is mechanistically coherent but empirically vacant.
- BPC-157 → VEGFR2-Akt-eNOS up-regulation (angiogenesis, Grade B, PMID 27847966); NO system modulation; GHR up-regulation (Grade C, in vitro only)
- TB-500 → G-actin sequestration (Grade A biochemistry); ATP synthase β-subunit binding KD = 12 nM (Grade B, PMID 21106936); Notch1/4 angiogenesis (VEGF-independent)
- Combination logic → largely non-overlapping pathways; plausible synergy — but no combination study in any model
No discrete molecular receptor has been identified for BPC-157. VEGFR2 up-regulation is the most independently replicated target.
TB-500 tendon/ligament evidence: absent (Grade D). No study has examined TB-500 in any tendon or ligament injury model.
Evidence vs. Projection
Evidence-backed (well-supported)
- BPC-157 counteracts NSAID-induced gastric damage in rodents (PMID 28839430)
- BPC-157 activates VEGFR2-Akt-eNOS axis in vivo + in vitro, independently replicated (PMID 27847966)
- TB-500 binds ATP synthase β-subunit with KD = 12 nM, functionally validated (PMID 21106936)
- WADA has documented positive TB-500 doping cases; detection assay validated (PMID 37515313)
- Oral bioavailability claims for both peptides lack primary citations
Projection only (no direct evidence)
- Human musculoskeletal efficacy for either peptide (extrapolated from rodent)
- Combination synergy or additivity (theoretically plausible, unstudied)
- Any specific human dosing protocol
- BPC-157 half-life in humans
- Anti-inflammatory efficacy of NSAIDs when combined with BPC-157 at injury sites
- BPC-157 F-actin effects (no PubMed-indexed primary study; widely cited in grey-market literature)
NSAID Co-Use: Clinically Actionable Counseling Gap
The ambiguity is real and unresolved.
| Effect | Evidence | Direction |
|---|---|---|
| BPC-157 vs. NSAID gastric damage | Rodent: robust gastroprotection | BPC-157 beneficial |
| BPC-157 vs. NSAID anti-inflammatory efficacy at injury site | No study exists | Unknown — theoretically may counteract |
Counseling implication: Short-term NSAID use for pain control may be acceptable with BPC-157 for gastric protection. Chronic NSAID use should involve a physician. Monitor injury-site inflammation closely if co-using. Neither the benefit nor the risk can be quantified.
WADA / Anti-Doping Risk
TB-500 is on the WADA Monitoring Program (2024/2025) — not currently prohibited, but being tracked. Positive doping cases in athletes have been documented despite the monitoring-only status. WADA’s Ac-Tβ1-14 metabolite detection assay (PMID 37515313, LOD 0.19 ng/mL) is validated.
Guidance for competitive athletes: Do not use TB-500 if subject to WADA or national anti-doping testing. Consult your national anti-doping agency (e.g., USADA) before use. The human detection window for grey-market TB-500 is not established.
BPC-157 is in a regulatory grey zone — not explicitly prohibited by name but not guaranteed WADA-safe.
Comparison to Standard of Care
| Intervention | Evidence Grade (tendinopathy/MSK) |
|---|---|
| Physical therapy (eccentric loading) | A — first-line standard |
| PRP injections | B− — 33 RCTs, 2,025+ subjects |
| NSAIDs | B — symptomatic relief; chronic use may impair tendon healing |
| BPC-157 | C (preclinical only) |
| TB-500 | D (no tendon/ligament model; zero human data) |
| Combination | F (no combination study in any species) |
Registered Clinical Trials (2026+)
| Trial | Peptide | Indication | Est. Completion |
|---|---|---|---|
| NCT07437547 (BPC-HAMSTR) | BPC-157, Phase II | Acute hamstring strain | February 2027 |
| NCT07487363 (TBRIDGE-CV) | TB-500 fragment, Phase 1/2 | ASCVD | February 2027 |
Both: isFdaRegulatedDrug: false; not proceeding under FDA regulatory framework. Same sponsor (Hudson Biotech). First human musculoskeletal efficacy data for BPC-157 is years away.
Risks and Uncertainty
- P0 gaps: No human PK, no human MSK efficacy, no combination study, no long-term safety for either peptide
- Grey-market quality: No lot-to-lot verification, endotoxin testing, or sterility guarantee for either peptide
- Pregnancy: Contraindicated for both
- Active malignancy: Theoretical concern for both (growth promotion / metastatic spread)
- Anticoagulant co-use: Theoretical bleeding risk with BPC-157
- Site dominance: BPC-157 tendon/ligament data dominated by single Zagreb group; independent replication absent
Related Notes
- BPC-157 — individual peptide hub
- TB-500 — individual peptide hub
- Peptides MOC — peptide map and index
- Vitals Knowledge Map — top-level vault navigation
Aspirational links (concept exists, note not yet built): NSAID peptide interactions — needed to properly surface the NSAID co-use counseling gap at scale across peptide notes